Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Emergent BioSolutions Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024 May 10, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Reports First Quarter 2024 Financial Results May 01, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position May 01, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone May 01, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Announces Amendment to its Existing Credit Facility April 30, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 April 22, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis March 28, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility March 25, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results March 06, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024 February 29, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO February 21, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers BLCO EBS Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense January 11, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 January 09, 2024 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) November 28, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing November 24, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Reports Third Quarter 2023 Financial Results November 08, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023 October 30, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023 October 19, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors October 02, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS LQDA Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency August 30, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Reports Financial Results for Second Quarter 2023 August 08, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position August 08, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola July 31, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023 July 25, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use July 20, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Announces CEO Transition June 27, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic May 15, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT May 11, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions Reports Financial Results For First Quarter 2023 May 09, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023 April 19, 2023 From Emergent BioSolutions Via GlobeNewswire Tickers EBS Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.